JP2001524320A5 - - Google Patents

Download PDF

Info

Publication number
JP2001524320A5
JP2001524320A5 JP2000522279A JP2000522279A JP2001524320A5 JP 2001524320 A5 JP2001524320 A5 JP 2001524320A5 JP 2000522279 A JP2000522279 A JP 2000522279A JP 2000522279 A JP2000522279 A JP 2000522279A JP 2001524320 A5 JP2001524320 A5 JP 2001524320A5
Authority
JP
Japan
Prior art keywords
ligand
seq
nucleic acid
acid ligand
label
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000522279A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001524320A (ja
Filing date
Publication date
Priority claimed from US08/976,413 external-priority patent/US6127119A/en
Application filed filed Critical
Publication of JP2001524320A publication Critical patent/JP2001524320A/ja
Publication of JP2001524320A5 publication Critical patent/JP2001524320A5/ja
Withdrawn legal-status Critical Current

Links

JP2000522279A 1997-11-21 1998-11-19 組織標的に対する核酸リガンド Withdrawn JP2001524320A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/976,413 US6127119A (en) 1990-06-11 1997-11-21 Nucleic acid ligands of tissue target
US08/976,413 1997-11-21
PCT/US1998/025006 WO1999027138A1 (en) 1997-11-21 1998-11-19 Nucleic acid ligands of tissue target

Publications (2)

Publication Number Publication Date
JP2001524320A JP2001524320A (ja) 2001-12-04
JP2001524320A5 true JP2001524320A5 (enExample) 2009-09-10

Family

ID=25524076

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000522279A Withdrawn JP2001524320A (ja) 1997-11-21 1998-11-19 組織標的に対する核酸リガンド

Country Status (6)

Country Link
US (1) US6127119A (enExample)
EP (1) EP1032708A4 (enExample)
JP (1) JP2001524320A (enExample)
AU (1) AU750820B2 (enExample)
CA (1) CA2311164A1 (enExample)
WO (1) WO1999027138A1 (enExample)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232071B1 (en) * 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US7005260B1 (en) 2000-01-28 2006-02-28 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
DE10019154A1 (de) * 2000-04-18 2001-10-31 Univ Eberhard Karls Zellbindende Nukleinsäuremoleküle (Aptamere)
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
AU2001296305B2 (en) * 2000-09-26 2007-12-06 Duke University RNA aptamers and methods for identifying the same
PT1401853E (pt) 2001-05-25 2010-12-07 Univ Duke Modulador de oligonucleotídeos
US7206639B2 (en) * 2002-03-15 2007-04-17 Sarcos Investments Lc Cochlear drug delivery system and method
US7727969B2 (en) 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
WO2005059509A2 (en) * 2003-12-12 2005-06-30 Saint Louis University Biosensors for detecting macromolecules and other analytes
US8389710B2 (en) 2004-02-27 2013-03-05 Operational Technologies Corporation Therapeutic nucleic acid-3′-conjugates
US8318920B2 (en) * 2004-02-27 2012-11-27 Operational Technologies Corporation Therapeutic nucleic acid-3′-conjugates
US7910297B2 (en) * 2004-02-27 2011-03-22 Operational Technologies Corporation Therapeutic nucleic acid-3' -conjugates
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
CA2560756A1 (en) 2004-03-25 2005-10-06 The Feinstein Institute For Medical Research Methods and devices for reducing bleed time using vagus nerve stimulation
CN103045601B (zh) * 2004-04-22 2015-04-01 雷加多生物科学公司 改良的凝血因子调节物
AU2005323463B2 (en) 2004-12-27 2009-11-19 The Feinstein Institutes For Medical Research Treating inflammatory disorders by electrical vagus nerve stimulation
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
US7795009B2 (en) * 2005-06-15 2010-09-14 Saint Louis University Three-component biosensors for detecting macromolecules and other analytes
US8956857B2 (en) 2005-06-06 2015-02-17 Mediomics, Llc Three-component biosensors for detecting macromolecules and other analytes
EP1907410B1 (en) * 2005-06-10 2012-07-04 Saint Louis University Methods for the selection of aptamers
US7811809B2 (en) * 2005-06-15 2010-10-12 Saint Louis University Molecular biosensors for use in competition assays
US7964356B2 (en) * 2007-01-16 2011-06-21 Somalogic, Inc. Method for generating aptamers with improved off-rates
US8975026B2 (en) 2007-01-16 2015-03-10 Somalogic, Inc. Method for generating aptamers with improved off-rates
WO2009029614A1 (en) 2007-08-27 2009-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
US20090163437A1 (en) * 2007-10-16 2009-06-25 Regado Biosciences, Inc. Steady-state subcutaneous administration of aptamers
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
WO2009146030A1 (en) 2008-03-31 2009-12-03 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of t-cell activity
US8703416B2 (en) 2008-07-17 2014-04-22 Somalogic, Inc. Method for purification and identification of sperm cells
US8412338B2 (en) 2008-11-18 2013-04-02 Setpoint Medical Corporation Devices and methods for optimizing electrode placement for anti-inflamatory stimulation
EP2703816B1 (en) 2008-11-21 2016-10-05 Saint Louis University Biosensor for detecting multiple epitopes on a target
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
AU2010256511B2 (en) 2009-06-03 2016-01-14 Tobira Therapeutics, Inc. Nucleic acid modulators of glycoprotein VI
CN102573986B (zh) 2009-06-09 2016-01-20 赛博恩特医疗器械公司 用于无导线刺激器的具有袋部的神经封套
US8236570B2 (en) 2009-11-03 2012-08-07 Infoscitex Methods for identifying nucleic acid ligands
US8841429B2 (en) 2009-11-03 2014-09-23 Vivonics, Inc. Nucleic acid ligands against infectious prions
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
WO2014169145A1 (en) 2013-04-10 2014-10-16 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
EP2515996B1 (en) 2009-12-23 2019-09-18 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US20110165037A1 (en) * 2010-01-07 2011-07-07 Ismagilov Rustem F Interfaces that eliminate non-specific adsorption, and introduce specific interactions
US9040287B2 (en) 2010-02-12 2015-05-26 Mediomics, Llc Molecular biosensors capable of signal amplification
US12172017B2 (en) 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
EP2707094B1 (en) 2011-05-09 2016-02-03 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
WO2013119602A1 (en) 2012-02-06 2013-08-15 President And Fellows Of Harvard College Arrdc1-mediated microvesicles (armms) and uses thereof
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
ES2851924T3 (es) 2014-02-05 2021-09-09 Univ Deakin Estructura artificial de aptámero
US10274484B2 (en) 2014-09-12 2019-04-30 Mediomics Llc Molecular biosensors with a modular design
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
US9816080B2 (en) 2014-10-31 2017-11-14 President And Fellows Of Harvard College Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
US11406833B2 (en) 2015-02-03 2022-08-09 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US11634704B2 (en) 2015-04-13 2023-04-25 Research Foundation Of The City University Of New York Ligand-guided-selection method for screening antigen-specific ligands
US10253314B2 (en) * 2015-04-13 2019-04-09 Research Foundation Of The City University Of New York Ligand-guided-selection method for screening antigen-specific ligands
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
WO2017127758A1 (en) 2016-01-20 2017-07-27 Setpoint Medical Corporation Implantable microstimulators and inductive charging systems
WO2017127756A1 (en) 2016-01-20 2017-07-27 Setpoint Medical Corporation Control of vagal stimulation
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
EP3518981A4 (en) 2016-10-03 2020-06-10 President and Fellows of Harvard College THERAPEUTIC RNA DELIVERY THROUGH ARRDC1 MICROVESICLES
WO2019036470A1 (en) 2017-08-14 2019-02-21 Setpoint Medical Corporation TESTING TEST FOR STIMULATION OF NERVE WAVE
US11660443B2 (en) 2018-04-20 2023-05-30 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
AU2020272128B9 (en) 2019-04-12 2025-11-20 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
WO2021092651A1 (en) * 2019-11-14 2021-05-20 i-ZUM-X Pty Ltd Method of detection of fibrin clots
IL298193B2 (en) 2020-05-21 2024-01-01 Feinstein Institutes For Medical Research Systems and methods for vagus nerve stimulation
US12444497B2 (en) 2021-05-17 2025-10-14 Setpoint Medical Corporation Neurostimulation parameter authentication and expiration system for neurostimulation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986005803A1 (fr) * 1985-03-30 1986-10-09 Marc Ballivet Procede d'obtention d'adn, arn, peptides, polypeptides ou proteines, par une technique de recombinaison d'adn
WO1989006694A1 (en) * 1988-01-15 1989-07-27 Trustees Of The University Of Pennsylvania Process for selection of proteinaceous substances which mimic growth-inducing molecules
US5688935A (en) * 1990-06-11 1997-11-18 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands of tissue target
US5270163A (en) * 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5750342A (en) * 1990-06-11 1998-05-12 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands of tissue target
IE920562A1 (en) * 1991-02-21 1992-08-26 Gilead Sciences Aptamer specific for biomolecules and method of making
WO1994006934A1 (en) * 1992-09-11 1994-03-31 Duke University Method for deriving epitopes
US5614503A (en) * 1993-11-12 1997-03-25 Aronex Pharmaceuticals, Inc. Amphipathic nucleic acid transporter
DE69637605D1 (de) * 1995-05-03 2008-08-28 Bayer Schering Pharma Ag Verfahren zur Identifizierung von Nukleinsäureliganden für Gewebsziele

Similar Documents

Publication Publication Date Title
JP2001524320A5 (enExample)
JP2001520886A5 (enExample)
EP1162206A3 (en) Peptide nucleic acids
JP2002531053A5 (enExample)
JP2004511201A5 (enExample)
JP2003522514A5 (enExample)
JP2002527052A5 (enExample)
CA2196555A1 (en) Vr-2332 viral nucleotide sequence and methods of use
EP1130094A3 (en) Primers for synthesizing full length cDNA clones and their use
JP2004528809A5 (enExample)
JP2003525623A5 (enExample)
JP2004194588A5 (enExample)
JP2002527354A5 (enExample)
Shih et al. Intron existence predated the divergence of eukaryotes and prokaryotes
JP2003509018A5 (enExample)
JP2004524806A5 (enExample)
JPWO2023015309A5 (enExample)
EP0816504A3 (en) Platelet activating factor acetylhdrolase, and gene thereof
HU228811B1 (hu) Technéciummal és réniummal radioaktívan jelölt, glikozilált oktreotidszármazékok
WO2003004603A3 (en) Methods of modulating pharmacokinetics of oligonucleotides
JPH10210974A5 (enExample)
WO2001030987A3 (en) Tankyrase h, compositions involved in the cell cycle and methods of use
AU1602497A (en) Nucleotide sequence from goat liver
JP2005504525A5 (enExample)
WO2002016586A3 (en) Adenosine deaminase homolog